A detailed history of Loomis Sayles & CO L P transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Loomis Sayles & CO L P holds 1,516,123 shares of SUPN stock, worth $54 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,516,123
Previous 1,556,161 2.57%
Holding current value
$54 Million
Previous $41.6 Million 13.56%
% of portfolio
0.06%
Previous 0.06%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$25.77 - $35.16 $1.03 Million - $1.41 Million
-40,038 Reduced 2.57%
1,516,123 $47.3 Million
Q2 2024

Aug 13, 2024

SELL
$25.99 - $33.85 $1.07 Million - $1.4 Million
-41,256 Reduced 2.58%
1,556,161 $41.6 Million
Q1 2024

May 14, 2024

SELL
$27.11 - $35.17 $1.06 Million - $1.37 Million
-39,073 Reduced 2.39%
1,597,417 $54.5 Million
Q4 2023

Feb 13, 2024

SELL
$22.72 - $29.68 $2.13 Million - $2.78 Million
-93,779 Reduced 5.42%
1,636,490 $47.4 Million
Q3 2023

Nov 09, 2023

BUY
$27.57 - $32.91 $3.78 Million - $4.51 Million
136,964 Added 8.6%
1,730,269 $47.7 Million
Q2 2023

Aug 11, 2023

BUY
$29.91 - $38.73 $994,298 - $1.29 Million
33,243 Added 2.13%
1,593,305 $47.9 Million
Q1 2023

May 11, 2023

BUY
$34.93 - $42.03 $18,408 - $22,149
527 Added 0.03%
1,560,062 $56.5 Million
Q4 2022

Feb 10, 2023

SELL
$31.09 - $37.88 $1.3 Million - $1.58 Million
-41,768 Reduced 2.61%
1,559,535 $55.6 Million
Q3 2022

Nov 14, 2022

SELL
$28.79 - $35.41 $278,082 - $342,025
-9,659 Reduced 0.6%
1,601,303 $54.2 Million
Q2 2022

Aug 05, 2022

SELL
$25.33 - $34.25 $473,620 - $640,406
-18,698 Reduced 1.15%
1,610,962 $46.6 Million
Q1 2022

May 13, 2022

SELL
$28.51 - $32.9 $1.18 Million - $1.37 Million
-41,554 Reduced 2.49%
1,629,660 $52.7 Million
Q4 2021

Feb 14, 2022

BUY
$26.37 - $34.22 $544,461 - $706,540
20,647 Added 1.25%
1,671,214 $48.7 Million
Q3 2021

Nov 12, 2021

BUY
$23.54 - $31.39 $741,557 - $988,847
31,502 Added 1.95%
1,650,567 $44 Million
Q2 2021

Aug 13, 2021

BUY
$26.72 - $33.19 $31.7 Million - $39.4 Million
1,186,742 Added 274.5%
1,619,065 $49.9 Million
Q1 2021

May 17, 2021

BUY
$24.15 - $31.45 $1.99 Million - $2.59 Million
82,195 Added 23.48%
432,323 $11.3 Million
Q4 2020

Feb 12, 2021

SELL
$17.7 - $25.81 $210,169 - $306,467
-11,874 Reduced 3.28%
350,128 $8.81 Million
Q3 2020

Nov 12, 2020

SELL
$20.2 - $25.05 $30,300 - $37,575
-1,500 Reduced 0.41%
362,002 $7.54 Million
Q2 2020

Aug 14, 2020

SELL
$17.09 - $24.89 $209,677 - $305,375
-12,269 Reduced 3.27%
363,502 $8.63 Million
Q1 2020

May 15, 2020

SELL
$14.45 - $24.69 $3.74 Million - $6.38 Million
-258,530 Reduced 40.76%
375,771 $6.76 Million
Q4 2019

Feb 14, 2020

SELL
$19.93 - $29.13 $9.61 Million - $14 Million
-482,266 Reduced 43.19%
634,301 $15 Million
Q3 2019

Nov 13, 2019

BUY
$25.47 - $33.37 $2.88 Million - $3.78 Million
113,138 Added 11.28%
1,116,567 $30.7 Million
Q2 2019

Aug 14, 2019

BUY
$29.96 - $38.87 $17.3 Million - $22.5 Million
578,301 Added 136.03%
1,003,429 $33.2 Million
Q1 2019

May 15, 2019

SELL
$32.77 - $41.99 $617,911 - $791,763
-18,856 Reduced 4.25%
425,128 $14.9 Million
Q4 2018

Feb 14, 2019

SELL
$30.84 - $49.51 $3.99 Million - $6.4 Million
-129,228 Reduced 22.54%
443,984 $14.7 Million
Q3 2018

Nov 13, 2018

SELL
$42.7 - $56.55 $275,842 - $365,313
-6,460 Reduced 1.11%
573,212 $28.9 Million
Q2 2018

Aug 14, 2018

BUY
$44.1 - $59.85 $247,797 - $336,297
5,619 Added 0.98%
579,672 $34.7 Million
Q1 2018

May 11, 2018

SELL
$37.15 - $46.9 $755,668 - $953,992
-20,341 Reduced 3.42%
574,053 $26.3 Million
Q4 2017

Feb 14, 2018

SELL
$36.4 - $42.6 $1.97 Million - $2.3 Million
-54,012 Reduced 8.33%
594,394 $23.7 Million
Q3 2017

Nov 14, 2017

SELL
$36.75 - $49.65 $719,675 - $972,295
-19,583 Reduced 2.93%
648,406 $25.9 Million
Q2 2017

Aug 14, 2017

BUY
N/A
667,989
667,989 $28.8 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.